Skip to main content

Table 2 Comparing heart rate variability (HRV) time-domain and frequency-domain measures at baseline and after completion of treatment

From: Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring

Variable Baseline (n = 50) After completion of treatment (n = 50) p value
HRV time-domain measures
SDNN, ms 121.70 ± 24.24 133.56 ± 50.79 0.122
SDANN, ms 111.99 ± 31.13 113.03 ± 79.76 0.913
RMSSD, ms 36.68 ± 19.49 105.06 ± 118.48 0.21
HRV triangular index 37.39 ± 16.69 27.21 ± 12.15 0.31
HRV frequency-domain measures
ULF power, ms2 11308 ± 4001.5 7270.4 ± 4551.4 0.092
VLF power, ms2 1566.5 ± 1454.4 1331.1 ± 865.41 0.876
LF power, ms2 1103.2 ± 1290.6 2584.1 ± 4392.2 0.225
HF power, ms2 709.28 ± 724.54 4323.2 ± 8251.2 0.165
LF/HF ratio 2.85 ± 3.62 1.39 ± 0.846 0.194
  1. Continuous variables are expressed as mean and standard deviation
  2. HRV means heart rate variability; SDNN means standard deviation of NN intervals; SDANN means standard deviation of the average NN intervals for each 5 min segment of a 24-h HRV recording; RMSSD means root mean square of successive RR interval differences; ULF power means absolute power of the ultra-low-frequency band (≤ 0.003 Hz); VLF power means absolute power of the very-low-frequency band (0.0033–0.04 Hz); LF power means absolute power of the low-frequency band (0.04–0.15 Hz); HF power means absolute power of the high-frequency band (0.15–0.4 Hz)